β-lapachone reduces cell viability, migration, and epithelial–mesenchymal transition in mammary tumor spheroids
By
Laura Lacerda Coelho
Matheus Menezes Vianna
Debora Moraes da Silva
Beatriz Matheus de Souza Gonzaga
Roberto Rodrigues Ferreira
Claudia Mara Lara Melo Coutinho
Fatima Cristina Mendes Magalhães
Edmilson José Maria
Rodrigo Rodrigues de Oliveira
Pedro Paulo de Abreu Manso
Marcelo Alex de Carvalho
Fernando Regla Vargas
Luciana Ribeiro Garzoni
November 26, 2025
Clinical Scorecard: β-lapachone reduces cell viability, migration, and epithelial–mesenchymal transition in mammary tumor spheroids
At a Glance
Category Detail
Condition Breast cancer Key Mechanisms Induces cell cycle arrest, promotes cell death, modulates epithelial-mesenchymal transition (EMT) Target Population Women with breast cancer Care Setting In vitro studies using 3D mammary tumor spheroids
Key Highlights
β-lapachone exhibits cytotoxic effects on MCF-7 breast cancer spheroids. Reduces cell viability and migration in mammary tumor spheroids. Modulates EMT by restoring E-cadherin and downregulating mesenchymal markers. Guideline-Based Recommendations
Diagnosis
Utilize 3D cell culture systems for more accurate tumor modeling. Management
Consider β-lapachone as a potential therapeutic agent in breast cancer treatment. Monitoring & Follow-up
Assess cell viability and migration using flow cytometry and microscopy. Risks
Monitor for potential cytotoxic effects at varying concentrations. Patient & Prescribing Data
Patients with breast cancer, particularly those with metastatic potential.
β-lapachone shows promise in reducing metastasis and improving treatment outcomes.
Clinical Best Practices
Incorporate 3D culture models in drug screening for breast cancer therapies. Evaluate the effects of β-lapachone in combination with existing treatments. Related Resources & Content
